|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 369.19 USD | +1.52% |
|
-3.94% | +12.80% |
| 02-12 | Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM | |
| 02-12 | European Commission approves Amgen's Uplizna® for generalized myasthenia gravis | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 6.27B | 7.99B | 7.63B | 10.94B | 11.97B | |||||
Short Term Investments | 4.38B | 48M | 1.68B | - | - | |||||
Total Cash And Short Term Investments | 10.65B | 8.04B | 9.3B | 10.94B | 11.97B | |||||
Accounts Receivable, Total | 4.52B | 4.9B | 5.56B | 7.27B | 6.78B | |||||
Other Receivables | 799M | 944M | 829M | 674M | 719M | |||||
Total Receivables | 5.32B | 5.84B | 6.39B | 7.94B | 7.5B | |||||
Inventory | 3.89B | 4.09B | 4.93B | 9.52B | 7B | |||||
Prepaid Expenses | 1.16B | 1.22B | 1.2B | 1.65B | 2.14B | |||||
Other Current Assets, Total | 124M | 200M | 355M | 281M | 419M | |||||
Total Current Assets | 21.14B | 19.38B | 22.19B | 30.33B | 29.03B | |||||
Gross Property Plant And Equipment | 14.27B | 14.55B | 15.29B | 16.4B | 17.49B | |||||
Accumulated Depreciation | -8.98B | -8.8B | -9.28B | -9.81B | -10.39B | |||||
Net Property Plant And Equipment | 5.3B | 5.75B | 6.01B | 6.59B | 7.1B | |||||
Long-term Investments | 1.18B | 4.5B | 3.16B | 4.45B | 4.77B | |||||
Goodwill | 14.69B | 14.89B | 15.53B | 18.63B | 18.64B | |||||
Other Intangibles, Total | 16.59B | 15.18B | 16.08B | 32.64B | 27.7B | |||||
Other Long-Term Assets, Total | 4.06B | 1.46B | 2.16B | 4.51B | 4.6B | |||||
Total Assets | 62.95B | 61.16B | 65.12B | 97.15B | 91.84B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 1.42B | 1.37B | 1.57B | 1.59B | 1.91B | |||||
Accrued Expenses, Total | 7.67B | 8.26B | 9.49B | 12.37B | 13.67B | |||||
Current Portion of Long-Term Debt | 91M | 87M | 1.59B | 1.44B | 3.55B | |||||
Current Portion of Leases | 153M | 145M | 156M | 119M | 107M | |||||
Current Income Taxes Payable | 828M | 701M | 1.2B | 1.66B | 2.58B | |||||
Other Current Liabilities | 1.49B | 1.62B | 1.68B | 1.2B | 1.28B | |||||
Total Current Liabilities | 11.65B | 12.18B | 15.69B | 18.39B | 23.1B | |||||
Long-Term Debt | 32.9B | 33.22B | 37.35B | 63.17B | 56.55B | |||||
Long-Term Leases | 306M | 525M | 539M | 691M | 673M | |||||
Deferred Tax Liability Non Current | - | - | - | 2.35B | 1.62B | |||||
Other Non Current Liabilities | 8.68B | 8.53B | 7.88B | 6.32B | 4.02B | |||||
Total Liabilities | 53.54B | 54.46B | 61.46B | 90.92B | 85.96B | |||||
Common Stock, Total | 31.8B | 32.1B | 32.51B | 33.07B | 33.53B | |||||
Retained Earnings | -21.41B | -24.6B | -28.62B | -26.55B | -27.59B | |||||
Comprehensive Income and Other | -985M | -796M | -231M | -289M | -66M | |||||
Total Common Equity | 9.41B | 6.7B | 3.66B | 6.23B | 5.88B | |||||
Total Equity | 9.41B | 6.7B | 3.66B | 6.23B | 5.88B | |||||
Total Liabilities And Equity | 62.95B | 61.16B | 65.12B | 97.15B | 91.84B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 578M | 557M | 534M | 536M | 537M | |||||
ECS Total Common Shares Outstanding | 578M | 558M | 534M | 535M | 537M | |||||
Book Value / Share | 16.27 | 12 | 6.86 | 11.64 | 10.95 | |||||
Tangible Book Value | -21.87B | -23.37B | -27.95B | -45.04B | -40.46B | |||||
Tangible Book Value Per Share | -37.81 | -41.86 | -52.34 | -84.12 | -75.36 | |||||
Total Debt | 33.44B | 33.98B | 39.64B | 65.42B | 60.88B | |||||
Net Debt | 22.8B | 25.94B | 30.34B | 54.48B | 48.91B | |||||
Debt Equivalent Oper. Leases | 1.51B | 1.59B | 1.49B | 1.44B | 1.62B | |||||
Equity Method Investments, Total | 496M | 3.63B | 2.45B | 251M | 637M | |||||
Account Code - Inventory Valuation | 5 | 5 | 5 | 5 | 5 | |||||
Inventories - Raw Materials, Total | 486M | 647M | 828M | 993M | 818M | |||||
Inventories - Work In Process, Total | 2.44B | 2.37B | 3.1B | 5.75B | 4.12B | |||||
Inventories - Finished Goods, Total | 970M | 1.07B | 1B | 2.78B | 2.06B | |||||
Land - (BS) | 259M | 279M | 292M | 339M | 346M | |||||
Buildings, Total | 3.86B | 4.03B | 4.2B | 4.51B | 4.8B | |||||
Machinery, Total | 6.53B | 6.68B | 6.86B | 7.09B | 7.23B | |||||
Full Time Employees | 24.3K | 24.2K | 25.2K | 26.7K | 28K | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 32M | 26M | 22M | 28M | 38M |
- Stock Market
- Equities
- AMGN Stock
- Financials Amgen Inc.
- Balance Sheet
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















